These findings indicate that circulating CAMs and KLF4 might be used as potential biomarkers for predicting the prognosis of acute CIS and also provide a proof of concept for the further translational validation of overexpress of KLF4 for the treatment of CIS patients in clinical practice in the future. The gene discussed is KLF4; the disease is in situ carcinoma.